Fetal growth restriction is a leading cause of stillbirth and miscarriage and often associated with inappropriate placental development and/or function. The placenta is responsible for coordinating the transfer of nutrients and oxygen between mother and baby during pregnancy and usually disposed after birth. Current treatment options for placental dysfunction during pregnancy are limited however, with the advances in nanomedicine potential treatments are emerging. In this project, we have developed a non-viral, placenta-specific transgene delivery system that targets placental dysfunction. Using both a guinea-pig model of fetal growth restriction and human placenta culture models, we are investigating the efficacy of gene transfer and placenta-specific expression of growth factors in correcting inadequate placental function and fetal growth. The overall goal is to develop a therapy for pregnant women that targets the placenta directly and is effective in improving fetal growth that may be used to prevent pregnancy complications such as stillbirth, miscarriage and preterm delivery.